Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual deficiency of DPD and UGT1A1 in a case of colon cancer.
Rawlley B, Diab O, Al-Rajabi R, Carroll E, Melancon T, Kasi A. Rawlley B, et al. Pharmacogenomics. 2020 Dec;21(18):1265-1269. doi: 10.2217/pgs-2020-0097. Epub 2020 Nov 18. Pharmacogenomics. 2020. PMID: 33203301 No abstract available.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant.
Khan QJ, Bivona CR, Martin GA, Zhang J, Liu B, He J, Li KH, Nelson M, Williamson S, Doolittle GC, Sun W, Mudaranthakam DP, Streeter NR, McGuirk JP, Al-Rajabi R, Hoffmann M, Kasi A, Parikh RA, Zhong C, Mitchell L, Pessetto ZY, Pathak H, Ghosh A, LaFaver S, Sharma P, Godwin AK. Khan QJ, et al. JAMA Oncol. 2022 Jul 1;8(7):1053-1058. doi: 10.1001/jamaoncol.2022.0752. JAMA Oncol. 2022. PMID: 35446353 Free PMC article.
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.
Saeed A, Park R, Dai J, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Saeed A, Ripp J, Collins Z, Mulvaney K, Shugrue M, Firth-Braun J, Godwin AK, Madan R, Phadnis M, Sun W. Saeed A, et al. Cell Rep Med. 2023 Feb 21;4(2):100916. doi: 10.1016/j.xcrm.2023.100916. Epub 2023 Jan 25. Cell Rep Med. 2023. PMID: 36702123 Free PMC article. Clinical Trial.
44 results